Re-Examining the Role of High-Dose Chemotherapy in the Treatment of Light Chain Amyloidosis

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 14-19

  Devine, Steven M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Light chain amyloidosis; Stem cell; Therapy; Transplantation

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PLERIXAFOR; POMALIDOMIDE; PROTEASOME INHIBITOR; THALIDOMIDE;

AMYLOIDOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOTHERAPY; DRUG MEGADOSE; HIGH DOSE CHEMOTHERAPY; HUMAN; LIGHT CHAIN AMYLOIDOSIS; LONG TERM SURVIVAL; META ANALYSIS (TOPIC); MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL MOBILIZATION;

LIGHT CHAIN AMYLOIDOSIS; STEM CELL; THERAPY; TRANSPLANTATION;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIVIDUALIZED MEDICINE; MELPHALAN; PATIENT SELECTION; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84890934714     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.015     Document Type: Review

References (76)

1. Comenzo R.L. How I treat amyloidosis. Blood 2009, 114:3147-3157.
2. Cibeira M.T., Sanchorawaia V., Seldin D.C., et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011, 118:4346-4352.
3. Leung N., Nasr S.H., Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2012, 120:3206-3213.
4. Schönland S.O., Hegenbart U., Bochtler T., et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012, 119:488-493.
5. Gatt M.E., Palladini G. Light chain amyloidosis 2012: a new era. Br J Haematol 2013, 160:582-598.
6. Comenzo R.L., Vosburgh E., Falk R.H., et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662-3670.
7. Gertz M.A. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013, 88:416-425.
8. Cordes S., Dispenzieri A., Lacy M.Q., et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012, 118:6105-6109.
9. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for al amyloidosis. NEng J Med 2007, 357:1083-1093.
10. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. NEng J Med 2008, 358:91-93.
11. Mhaskar R., Kumar A., Behera M., et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant 2009, 15:893-902.
12. Mehta J., Dispenzieri A., Gertz M.A. High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biol Blood Marrow Transplant 2010, 16:138-140.
13. Merlini G., Wechalekar A.D., Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013, 121:5124-5130.
14. Gratwohl A., Baldomero H., Aljurf M., et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010, 303:1617-1624.
15. Available at: http://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf.
16. Rosenzweig M., Giralt S., Landau H. Light-chain amyloidosis: SCT, novel agents and beyond. Bone Marrow Transplant 2013, 48:1022-1027.
17. Palladini G., Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011, 23:214-220.
18. Sanchorawala V., Hoering A., Seldin D.C., et al. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant 2013 Jul 15, [Epub ahead of print]. 10.1038/bmt.2013.98.
19. Landau H, etal. Risk-adapted melphalan and stem cell transplant for systemic light chain amyloidosis: a single institution experience. ASH Annual Meeting Abstracts 2012 Blood 2012;120:3109.
20. Comenzo RL, etal. Long-term outcomes of patients with systemic light chain Amyloidosis (AL) treated at diagnosis with risk-adapted stem cell transplant and consolidation with novel agents. ASH Annual Meeting Abstracts 2012. Blood 2012;120:3150.
21. Kumar S.K., Gertz M.A., Lacy M.Q., et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011, 86:12-18.
22. Cohen A.D., Zhou P., Chou J., et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007, 139:224-233.
23. Kristen A.V., Giannitsis E., Lehrke S., et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010, 116:2455-2461.
24. Kumar S., Dispenzieri A., Lacy M.Q., et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. JClin Oncol 2012, 30:989-995.
25. Gillmore J.D., Hawkins P.N. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol 2013, 9:574-586.
26. Esplin B.L., Gertz M.A. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol 2013, 38:53-96.
27. Perfetti V., Palladini G., Casarini S., et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 2012, 119:144-150.
28. Dubrey S.W., Comenzo R.L. Amyloid diseases of the heart: current and future therapies. QJM 2012, 105:617-631.
29. Dispenzieri A., Gertz M.A., Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis?. Blood Rev 2012, 26:137-154.
30. Brambilla F., Lavatelli F., Di Silvestre D., et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012, 119:1844-1847.
31. Merlini G., Seldin D.C., Gertz M.A. Amyloidosis: pathogenesis and new therapeutic options. JClin Oncol 2011, 29:1924-1933.
32. Poshusta T.L., Sikkink L.A., Leung N., et al. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE 2009, 4:e5169.
33. Kyle R.A., Linos A., Beard C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]. Blood 1992, 79:1817-1822.
34. Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. NEng J Med 2003, 349:583-596.
35. Gertz M.A., Comenzo R., Falk R.H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005, 79:319-328.
36. Dispenzieri A., Dingli D., Kumar S.K., et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010, 85:57-759.
37. Palladini G., Dispenzieri A., Gertz M.A., et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. JClin Oncol 2012, 30:4541-4549.
38. Gertz M.A. Allaying and alleviating amyloid agony and anxiety. Blood 2013, 121:3301-3302.
39. Leung N., Glavey S.V., Kumar S., et al. Adetailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologica 2013, 98:988-992.
40. Wechalekar A.D., Schonland S.O., Kastritis E., et al. AEuropean collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013, 121:3420-3427.
41. Palladini G., Foli A., Milani P., et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012, 87:465-471.
42. Kumar S., Dispenzieri A., Katzmann J.A., et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010, 116:5126-5129.
43. Dispenzieri A., Seenithamby K., Lacy M.Q., et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant 2013, 48:1302-1307.
44. Sanchorawala V., Patel J.M., Sloan J.M., et al. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica 2013, 98:789-792.
45. Palladini G., Russo P., Milani P., et al. Aphase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013, 98:433-436.
46. Landau H., Hassoun H., Rosenzweig M.A., et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013, 27:823-828.
47. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 2013, 48:557-561.
48. Dinner S., Witteles W., Afghahi A., et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica 2013, 98:1593-1599.
49. Venner C.P., Lane T., Foard D., et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012, 119:4387-4390.
50. Shah GL, etal. Subcutaneous bortezomib in combination regimens in newly diagnosed patients with myeloma or systemic al amyloidosis: high response rates and minimal toxicity. ASH Annual Meeting Abstracts 2012;Blood 2012;120:2968.
51. Mikhael J.R., Schuster S.R., Jimenez-Zepeda V.H., et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012, 119:4391-4394.
52. Merlini G, etal. MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a phase 1 study. ASH Annual Meeting Abstracts 2012 Blood 2012;120:731.
53. Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood 2012, 119:4343-4345.
54. Kumar S.K., Hayman S.R., Buadi F.K., et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012, 119:4860-4867.
55. Kastritis E., Terpos E., Roussou M., et al. Aphase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012, 119:5384-5390.
56. Kastritis E., Wechalekar A.D., Dimopoulos M.A., et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. JClin Oncol 2010, 28:1031-1037.
57. Sitia R., Palladini G., Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy?. Haematologica 2007, 92:1302-1307.
58. Schönland S.O., Dreger P., de Witte T., Hegenbart U. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 2012, 47:895-905.
59. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with al amyloidosis: an 8-year study. Ann Inter Med 2004, 140:85-93.
60. Mollee P.N., Wechalekar A.D., Pereira D.L., et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2003, 33:271-277.
61. Goodman H.J., Gillmore J.D., Lachmann H.J., et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006, 134:417-425.
62. Dinner S., Witteles W., Witteles R., et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol 2013, 161:367-372.
63. Kourelis T.V., Kumar S.K., Gertz M.A., et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. JClin Oncol 2013 Oct 21, [epub ahead of print].
64. Paiva B., Vídriales M.B., Pérez J.J., et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 2011, 117:3613-3616.
65. Gillmore J.D., Goodman H.J., Lachmann H.J., et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006, 107:1227-1229.
66. Sanchorawala V., Wright D.G., Quillen K., et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007, 40:557-562.
67. Cowan A.J., Seldin D.C., Skinner M., et al. Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment. Biol Blood Marrow Transplant 2012, 18:1935-1938.
68. Dunn D., Vikas P., Jagasia M., Savani B.N. Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant 2012, 47:1136-1137.
69. Bayraktar U.D., Bashir Q., Qazilbash M., et al. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:344-356.
70. Blum W., Khoury H., Lin H.S., et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant 2003, 9:397-404.
71. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEng J Med 2012, 366:1770-1781.
72. Thomas A., Mailankody S., Korde N., et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012, 119:2731-2737.
73. Bodin K., Ellmerich S., Kahan M.C., et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468:93-97.
74. Coelho T., Adams D., Silva A., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. NEng J Med 2013, 369:819-829.
75. Lachmann H.J. Anew era in the treatment of amyloidosis?. NEng J Med 2013, 369:866-868.
76. Wall J.S., et al. AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils. PLoS ONE 2012, 7:e52686.